| RF_ID |
Disease Name |
2ndClass |
3rdClass |
4thClass |
Species |
RF_Name |
Association |
Condition |
PMID |
| 3974 |
Parkinson disease |
Biochemical factors |
|
|
Human |
toxicant N-(1,3-dimethylbutyl)-N'-phenyl-p-phenylenediamine quinone (6PPD-Q) |
RF |
|
38147746 |
| 3070 |
Parkinson disease |
Biochemical factors |
MRI image |
|
Human |
perivascular space (PVS) |
RF |
|
36097211 |
| 2436 |
Parkinson disease |
Biochemical factors |
MRI image |
|
Human |
paraventricular white matter hyperintensity (PVH) |
RF |
|
36097211 |
| 3544 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
a protective response to proteostatic stress, directed by the NRF1-sMAF complex |
RF |
people carrying the risk (A) allele of rs667897 |
29179108 |
| 3545 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
accumulation of p16(INK4a)-positive senescent astrocytes |
RF |
|
22984612 |
| 3547 |
Amyotrophic Lateral Sclerosis |
Biochemical factors |
|
|
mice |
age-related decreases in ADAR2(adenosine deaminase acting on RNA 2) activity |
RF |
|
22916266 |
| 3548 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
age-related increase in chemokine CCL11 |
RF |
antagonizing CCR3 may bring therapeutic benefits to?AD |
27878757 |
| 774 |
Parkinson disease |
Biochemical factors |
|
|
Human |
alpha-synuclein (NACP-Rep1) |
PF |
|
15670652 |
| 3741 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
amyloid beta (Aβ) misfolding |
RF |
|
33614887 |
| 2537 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Amyloid-β (Aβ)(42) |
RF |
|
21955816 |
| 3551 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
annexin A5 |
RF |
|
23576984 |
| 3540 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
anti-AT1R |
RF |
|
26401573 |
| 3552 |
Frontotemporal Dementia |
Biochemical factors |
|
|
Human |
apo(a) low molecular weight (MW |
RF |
|
14665416 |
| 3554 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
apoE protein activity |
RF |
|
7672107 |
| 3553 |
Amyotrophic Lateral Sclerosis |
Biochemical factors |
|
|
Human |
APOE(protein) |
RF |
|
11940705 |
| 3557 |
Amyotrophic Lateral Sclerosis |
Biochemical factors |
|
|
Human |
Ataxin-2 intermediate-length polyglutamine expansions |
RF |
|
21292779 |
| 3132 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Aβ misfolding(measured in blood plasma) |
RF |
|
31611055 |
| 3558 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
beta-amyloid (Abeta) accumulation |
RF |
|
29592889 |
| 2296 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
beta-amyloid precursor protein (APP) processing |
RF |
|
9041854 |
| 858 |
Alzheimer's Disease |
Biochemical factors |
|
|
Caenorhabditis elegans |
betaine |
PF |
both the presence and absence of 1 mM homocysteine; independent of the remethylation pathway but requires the transsulfuration pathway mediated by cystathionine-β-synthase |
30065790 |
| 3559 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Bleomycin hydrolase (BLH) |
RF |
|
20308784 |
| 3561 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Branched-chain amino acids (BCAAs) |
RF |
|
29802157 |
| 1671 |
Parkinson disease |
Biochemical factors |
|
|
Human |
calcium channel blocker |
RF |
|
33647030 |
| 3562 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
CB1 receptor desensitization |
RF |
Seven-month-old male 3xTg-AD mice |
29865071 |
| 3709 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
CD22 |
RF |
|
34140954 |
| 482 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
cerebrospinal fluid (CSF) Aβ42 |
PF |
patients with negative amyloid PET |
33667602 |
| 481 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
cerebrospinal fluid (CSF) Aβ42 |
PF |
patients with negative amyloid PET |
33667602 |
| 3566 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Complement Receptor 1 (CR1) Density |
RF |
|
30044434 |
| 3568 |
Parkinson disease |
Biochemical factors |
|
|
Human |
C-reactive protein (CRP) |
RF |
|
31057478 |
| 3570 |
Parkinson disease |
Biochemical factors |
|
|
Human |
C-reactive protein (CRP) |
RF |
|
31057478 |
| 1868 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
C-reactive protein (CRP) |
RF |
|
34538509 |
| 3569 |
Parkinson disease |
Biochemical factors |
|
|
Human |
C-reactive protein (CRP) |
RF |
|
31057478 |
| 3571 |
Alzheimer's Disease |
Biochemical factors |
PET imaging |
|
Human |
CSF AβPET(amyloid beta brain PET imaging) |
RF |
Associated with AD progression |
29982466 |
| 3572 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
CSF Tau(cerebrospinal fluid tau) and P-tau(phosphorylated tau) |
RF |
Associated with AD progression |
29982466 |
| 3573 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
decreased expression of FERMT2 |
RF |
|
27215977 |
| 1752 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
decreasing Aβ1-42 rates |
RF |
|
30250861 |
| 890 |
Neurodegenerative diseases |
Biochemical factors |
|
|
mice |
Deferoxamine |
PF |
|
33788818 |
| 3575 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
depression-related monoaminergic systems |
RF |
including serotonin and noradrenaline |
29685068 |
| 3576 |
Parkinson disease |
Biochemical factors |
|
|
Human |
disturbance of the plasmatic rate of Cu |
RF |
|
23868039 |
| 3578 |
Amyotrophic Lateral Sclerosis |
Biochemical factors |
|
|
Human |
dysregulation modulation of proteasome activity |
RF |
|
24450587 |
| 2346 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Fibroblast Growth Factor 21 (FGF21) |
RF |
|
33850218 |
| 883 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Fibroblast Growth Factor 21 (FGF21) |
PF |
|
33131010 |
| 3541 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
free copper |
RF |
|
23760784 |
| 859 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
glucose regulation |
PF |
|
31034991 |
| 1611 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
glycated hemoglobin (HbA1c) |
RF |
Model I: adjusted for age and sex |
28705834 |
| 1557 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
glycated hemoglobin (HbA1c) |
RF |
Model IV: adjusted for PFG CV and HbA1c CV along with all other confounders in model III |
28705834 |
| 1581 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
glycated hemoglobin (HbA1c) |
RF |
Model II: adjusted for age, sex, FPG,HbA1c, insured amount and insured unit (see Table 1), smoking, alcohol consumption, duration of diabetes, type of hypoglycemic drug, hypertension drug treatment, and obesity |
28705834 |
| 1576 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
glycated hemoglobin (HbA1c) |
RF |
Model III: adjusted for CAD, CHF, stroke, cancer, hyperlipidemia, hypertension, atrial fibrillation, chronic hepatitis, COPD, and hypoglycemia along with all other confounders in model II |
28705834 |
| 3583 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
H4K16ac enrichment |
RF |
related to aging |
29507413 |
| 3585 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
High CSF(cerebrospinal fluid) MCP-1(monocyte chemoattractant protein 1) |
RF |
Associated with AD progression |
29982466 |
| 3590 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
IL-17A/IL-23 axis |
RF |
|
30081688 |
| 861 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
increased expression of NUP160 |
PF |
|
27215977 |
| 3592 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
increased fibrillar amyloid-{beta} |
RF |
individuals with a family history of late-onset Alzheimer's;particularly in persons with an AD mother |
20231448 |
| 3593 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
increased gene dosage of MIR138-2 |
RF |
|
30909216 |
| 3675 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
indices of HbA1c variability |
RF |
|
32870568 |
| 3596 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
inhibition of angiotensin-converting enzyme (ACE) activity |
RF |
|
31072831 |
| 3598 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
intracellular iron accumulation |
RF |
|
24199959 |
| 887 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
Irisin |
PF |
|
33768561 |
| 3599 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
ischemia/HIF-1α |
RF |
|
24478626 |
| 1452 |
Parkinson disease |
Biochemical factors |
|
|
Human |
levodopa equivalent dose (LED) |
RF |
|
33505652 |
| 1765 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
lifetime-acquired loss of chromosome Y (LOY) |
RF |
in blood cells |
27231129 |
| 3864 |
Parkinson disease |
Biochemical factors |
|
|
Human |
Lipoprotein-Associated Phospholipase A2(Lp-PLA2) |
RF |
|
33958981 |
| 863 |
Parkinson disease |
Biochemical factors |
|
|
Human |
lncRNA AK021630 |
PF |
|
27151187 |
| 3601 |
Parkinson disease |
Biochemical factors |
|
|
Human |
lncRNA AL049437 |
RF |
|
27151187 |
| 3603 |
Parkinson disease |
Biochemical factors |
|
|
Human |
Loss of aromatase cytochrome P450 function |
RF |
|
18063054 |
| 3609 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
mammalian target of rapamycin (mTOR) |
RF |
Tg2576 mice |
29729422 |
| 2718 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Methionine synthase |
RF |
|
12876480 |
| 2699 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Methionine synthase |
RF |
|
12876480 |
| 2795 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Methionine synthase |
RF |
|
12876480 |
| 2656 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Methionine synthase |
RF |
|
12876480 |
| 3827 |
Parkinson disease |
Biochemical factors |
|
|
Human |
molecular architecture of dopaminergic networks |
RF |
|
33198485 |
| 2341 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
mtDNA sub-haplogroup H5 |
RF |
in particular for females and independently from the APOE genotype |
20700462 |
| 3616 |
Amyotrophic Lateral Sclerosis |
Biochemical factors |
|
|
Human |
mutations in neurofilaments |
RF |
|
16084104 |
| 3739 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
MWF; an in vivo marker of myelin content |
RF |
|
33638111 |
| 3617 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Myeloperoxidase(MPO) polymorphism |
RF |
|
9918702 |
| 893 |
Parkinson disease |
Biochemical factors |
|
|
rat |
Naringenin (NAR) |
PF |
Paraquat (PQ); PQ-induced neurotoxicity and neurodegeneration |
34655599 |
| 3618 |
Amyotrophic Lateral Sclerosis |
Biochemical factors |
|
|
Human |
neuronal apoptosis inhibitory protein |
RF |
|
29311650 |
| 885 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
Non-saponin fraction with rich polysaccharide (NFP) |
PF |
|
33422674 |
| 864 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
Pantoea agglomerans-derived lipopolysaccharide (LPSp) |
PF |
fed a high-fat diet, oral administration of LPSp at 0.3 or 1 mg/kg body weight.day for 18 weeks |
29856882 |
| 3620 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
pathogenic mutations in CSF1R TK domain |
RF |
in concert with TREM2, TYROBP, and GRN |
29544907 |
| 3700 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
perfluorooctane sulfonate (PFOS) |
RF |
|
34224775 |
| 3753 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
perfluorooctane sulfonate (PFOS) |
RF |
in older adults with normal kidney function |
33068581 |
| 3782 |
Amyotrophic Lateral Sclerosis |
Biochemical factors |
|
|
Human |
perivascular fibroblast |
RF |
|
33859435 |
| 3813 |
Lewy Body Disease |
Biochemical factors |
MRI image |
|
Human |
periventricular white matter hyperintensities (PWMH) |
RF |
|
34366356 |
| 3802 |
Lewy Body Disease |
Biochemical factors |
MRI image |
|
Human |
periventricular white matter hyperintensities (PWMH) |
RF |
|
34366356 |
| 3621 |
Amyotrophic Lateral Sclerosis |
Biochemical factors |
|
|
Human |
perturbations of the ER proteostasis network |
RF |
|
25913742 |
| 3765 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
plasma phosphorylated tau181 (p-tau181) |
RF |
|
33419453 |
| 3624 |
Alzheimer's Disease |
Biochemical factors |
|
|
mice |
plasmin (PL) |
RF |
Tg6799 transgenic mice (referred to as AD mice) are double-transgenic for human APP/Presenilin 1 |
30254165 |
| 882 |
Alzheimer's Disease |
Biochemical factors |
|
|
rat |
propylparaben (PPB) |
PF |
traumatic brain injury (TBI) |
33185606 |
| 889 |
Chronic Traumatic Encephalopathy |
Biochemical factors |
|
|
mice |
PUFAs (n-3 polyunsaturated fatty acids) |
PF |
|
33913741 |
| 3626 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
self-assembly of the Apolipoprotein E4 |
RF |
impacts on ε4/ε4 individuals more severely than those with ε3/ε4 |
31051176 |
| 3631 |
Frontotemporal Dementia |
Biochemical factors |
|
|
Human |
SORT1(the neuronal receptor for granulin) |
RF |
|
29555433 |
| 3633 |
Dementia with Lewy bodies |
Biochemical factors |
|
|
Human |
the Casp2-generated tau fragment Δtau314 |
RF |
|
31362787 |
| 891 |
Parkinson disease |
Biochemical factors |
|
|
Human |
Transferrin/Transferrin Receptor 2 (TfR2) |
PF |
significantly more pronounced in females rather than in males |
33323945 |
| 772 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
Trunk fat‐free mass |
PF |
|
33718584 |
| 2822 |
Parkinson disease |
Biochemical factors |
MRI image |
|
Human |
White matter hyperintensities (WMH) |
RF |
|
33782518 |
| 3692 |
Alzheimer's Disease |
Biochemical factors |
MRI image |
|
Human |
White matter hyperintensities (WMH) |
RF |
All patients were Aβ-positive (Aβpos-AD) |
34322985 |
| 3092 |
Parkinson disease |
Biochemical factors |
MRI image |
|
Human |
White matter hyperintensities (WMH) |
RF |
|
36097211 |
| 3830 |
Parkinson disease |
Biochemical factors |
MRI image |
|
Human |
White matter hyperintensities (WMH) |
RF |
higher levels of both WMH and indices of cerebrovascular disease pathologies in aging brains |
34724033 |
| 3639 |
Alzheimer's Disease |
Biochemical factors |
MRI image |
|
Human |
White matter hyperintensities(WMH) load |
RF |
|
30678723 |
| 694 |
Alzheimer's Disease |
Biochemical factors |
|
|
Human |
α-synuclein rs356182 variants |
PF |
|
30598082 |
| 3462 |
Creutzfeldt-Jakob disease |
Biochemical factors |
Biologically Active Substance |
Hormone |
Human |
human growth hormone extract |
RF |
received human growth hormone extract for various period of time (mean +/- SD, 2.9 years) |
8797466 |
| 362 |
Progressive Supranuclear Palsy |
Biochemical factors |
Biologically Active Substance |
Hormone |
Human |
Corticoids |
Not Related |
|
19864660 |
